Biparametric prostate MRIs take significantly less time than multiparametric exams, as they do not include a contrast-enhanced sequence. This also makes the abbreviated exams more cost-friendly.
Using an advanced MRI technique, experts were able to measure tissue susceptibility and detect subtle variances in iron levels throughout different regions of the brain associated with memory.
Evaluating LVDF with echocardiography or AI-powered electrocardiography can help identify individuals at an increased risk of developing atrial fibrillation, according to new data presented at the ASE 36th Annual Scientific Sessions.
Reuters reported that 500 institutions are linked to the proposals. In total, $50 million is up for grabs as part of HHS’ Autism Data Science Initiative.
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Insured or not, few Americans are immune to medical debt. And when a budget-busting event comes, it can significantly worsen such basic social determinants of health (SDOH) as housing security and food affordability.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.
Briefly trained in point-of-care cardiac ultrasound, 72% of second-year medical students obtained clinical-quality views from a mannequin and 61% made the correct diagnosis in a volunteer simulated patient.
Orthopedic cone-beam CT supplier CurveBeam AI has received the FDA’s breakthrough device designation for software that computes risk of fracture in patients with osteopenia.
